Rocket Pharmaceuticals (NASDAQ:RCKT) Earns “Buy” Rating from Chardan Capital
Chardan Capital reaffirmed their buy rating on shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) in a report published on Monday morning,Benzinga reports. The brokerage currently has a $62.00 target price on the biotechnology company’s stock. A number of other equities research analysts also recently issued reports on RCKT. JPMorgan Chase & Co. increased their […]
More Stories
OneAscent Financial Services LLC Invests $4.58 Million in First Merchants Co. (NASDAQ:FRME)
OneAscent Financial Services LLC purchased a new stake in First Merchants Co. (NASDAQ:FRME – Free Report) during the 3rd quarter,...
OneAscent Financial Services LLC Acquires 112 Shares of Exxon Mobil Co. (NYSE:XOM)
OneAscent Financial Services LLC increased its holdings in shares of Exxon Mobil Co. (NYSE:XOM – Free Report) by 1.0% during...
Meeder Advisory Services Inc. Acquires 163 Shares of Cummins Inc. (NYSE:CMI)
Meeder Advisory Services Inc. raised its holdings in shares of Cummins Inc. (NYSE:CMI – Free Report) by 3.8% in the...
Thrivent Financial for Lutherans Boosts Holdings in Invesco S&P 500 Top 50 ETF (NYSEARCA:XLG)
Thrivent Financial for Lutherans grew its stake in shares of Invesco S&P 500 Top 50 ETF (NYSEARCA:XLG – Free Report)...
Thrivent Financial for Lutherans Purchases 1,101,796 Shares of iShares U.S. Treasury Bond ETF (BATS:GOVT)
Thrivent Financial for Lutherans boosted its position in iShares U.S. Treasury Bond ETF (BATS:GOVT – Free Report) by 280.3% in...
Swiss National Bank Cuts Stock Holdings in PulteGroup, Inc. (NYSE:PHM)
Swiss National Bank trimmed its holdings in shares of PulteGroup, Inc. (NYSE:PHM – Free Report) by 0.6% in the 3rd...